Clinical Trial

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Study acronym: RASolute 304
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Protocol Amendment History 4 changes
notable Trial sites expanded: 43 -> 60 locations 2026-08-01
notable Trial sites expanded: 34 -> 43 locations 2026-07-08
notable Trial sites expanded: 17 -> 34 locations 2026-06-23
notable Trial sites expanded: 7 -> 15 locations 2026-04-07
Trial Details
NCT Number NCT07252232
Lead Sponsor Revolution Medicines, Inc.
Conditions Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Enrollment 500 participants
Start Date 2025-12-15
Primary Completion 2029-05-10 (estimated)
Study Completion 2030-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-31